[Effect of human fibroblast derived inhibitor on tumor and transformed cell proliferation and differentiation].
The effect of HFDI (human fibroblast derived inhibitor) on cell growth inhibition and differentiation of J6-1 (leukemia cell line). Namalva (Burkitt's lymphoma cell line), and fresh leukemic bone marrow cell cultures was studied. HFDI was found to inhibit tumor and leukemic cell growth as assayed by 3H-TdR incorporation, cell degeneration and necrosis, and to induce differentiation. We demonstrated that the characteristics of PHA-inhibited lymphocyte transformation were, in fact, identical to those of HFDI-inhibited degeneration and necrosis and HFDI-induced differentiation. It seems that necrosis was related to target cell sensitivity to HFDI.
Song
Y
Y
Institute of Hematology, Tianjin.
Wu
K
K
D001853:Bone Marrow / Q000473:pathology; D002051:Burkitt Lymphoma / Q000473:pathology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D006020:Glycopeptides / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology*; D008213:Lymphocyte Activation / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects
D006020:Glycopeptides; D006131:Growth Inhibitors; C020327:fibroblast proliferation inhibitor